Percutaneous coronary intervention in patients admitted with acute coronary syndrome within 6 months after COVID-19 (retrospective single-center study)

Abstract

BACKGROUND: Assessing clinical manifestations in patients during the period of destabilization of the course of coronary artery disease after COVID-19 coronavirus infection remains a clinical problem. Identifying features of coronary artery lesions in such patients will help to prevent the development of complications and may influence the tactics of active dynamic monitoring.

AIM: To evaluate the structure of coronary artery lesions and clinical manifestations in patients with acute coronary syndrome that developed within 6 months after COVID-19 new coronavirus infection.

MATERIALS AND METHODS: A comparative analysis of the results of coronary artery stenting in 157 patients admitted with acute coronary syndrome has been carried out. The 1st group included 69 patients who had COVID-19 (vaccinated — 24.6%) during the 6 months preceding acute coronary syndrome; in the 2nd — 88 patients without a history of COVID-19 (vaccinated — 42%). All the patients had drug-eluting stents implanted in the infarct-related artery. Long-term results have been observed in 151 (96.2%) patients.

RESULTS: Before the development of acute coronary syndrome, dispnoe was more often observed in patients of the 1st group (36; 52%) than in patients of the 2nd group (13; 14.8%). There were no focal neurological symptoms in the patients of both groups. Dizziness more often preceded acute coronary syndrome in the patients of the 1st group (26; 38.2%) compared to the control group (5; 5.7%). Decreased motivation and fatigue were detected in 27 (67.5%) patients in the 1st group, which was more common than in the 2nd group (13; 32.5%). Acute coronary syndrome with ST elevation was treated in 47 % and 38.6% of the patients in the 1st groups and the 2nd, respectively. The development of acute coronary syndrome with ST segment elevation with previous clinical manifestations of post-covid syndrome in the 1st group was observed in 95.8%, whereas in the absence of post-covid syndrome in 53.3%. The mean value of LVEF in patients who had COVID-19 was 55.9 ± 14%, which was significantly lower than in the patients in the control group (63.2 ± 5.5%; р < 0.001). During the course of coronavirus infection in the patients in the first group, lung damage of degrees I–II according to CT scan data was observed in 76.8% of the patients and in 23.2% of degrees III–IV. The frequency of lesions of the circumflex branch in the 1st group was 15.9%, in the 2nd — 11.4% (р = 0.403); of the right coronary artery — 33.3%, and 22.7% (р = 0.41); of the diagonal branch — 5.8%, and 3.4% (р = 0.47); of the left main coronary artery — 5.8%, and 6.8% (р = 0.79), of the left anterior descending branch — 52.2%, and 35.2% (р = 0.033), respectively. The incidence of vasospastic angina in the 1st group was 53.6%, in the 2nd — 15.9% (р < 0.0001). ST segment elevation in lead AVR as a manifestation of subendocardial ischemia was registered in the 1st group — 40.6%, the 2nd — 11.4% (р < 0.0001). All the patients had drug-eluting stents implanted in the infarct-related artery. Overall survival (in-hospital and long-term) was 100% for the first group and 100 % for the second one.

CONCLUSIONS: In the structure of coronary arteries lesions after COVID-19 new coronavirus infection in patients with acute coronary syndrome, damage to the anterior interventricular artery dominates (52.2%). The likelihood of having a left anterior descending lesion during the development of acute coronary syndrome with ST segment elevation in patients who have had COVID-19 is 1.5 times higher. The structure of clinical manifestations after COVID-19 in patients before the development of acute coronary syndrome is dominated by shortness of breath (52 %) and decreased motivation and fatigue (67.5 %).

Keywords

post-covid syndrome / acute coronary syndrome / coronary artery stenting

References

[1] Bokeriya LA, Milievskaya EB, Pryanishnikov VV, et al. Serdechno-sosudistaya khirurgiya — 2021. Bolezni i vrozhdennye anomalii sistemy krovoobrashcheniya. Moscow: A.N. Bakulev National Medical Research Center for Cardiovascular Surgery of the Russian Ministry of Health; 2022. 322 p. (In Russ.)

[2] Бокерия Л.А., Милиевская Е.Б., Прянишников В.В. и др. Сердечно-сосудистая хирургия — 2021. Болезни и врожденные аномалии системы кровообращения. Москва: НМИЦ ССХ им. А.Н. Бакулева, 2022. 322 с.

[3] Kazemi E, Mansoursamaei A, Bijan M, et al. The prognostic effect of ST-elevation in lead aVR on coronary artery disease, and outcome in acute coronary syndrome patients: a systematic review and meta-analysis. Eur J Med Res. 2022;27(1):302. DOI: 10.1186/s40001-022-00931-5

[4] Kazemi E., Mansoursamaei A., Bijan M. et al. The prognostic effect of ST-elevation in lead aVR on coronary artery disease, and outcome in acute coronary syndrome patients: a systematic review and meta-analysis // Eur. J. Med. Res. 2022. Vol. 27, No. 1. P. 302. DOI: 10.1186/s40001-022-00931-5

[5] Shpagina LA, Kozik VA, Shpagin IS, et al. Features of the phenotype and endotype of the course of acute coronary syndrome in medical workers who have suffered a new coronavirus infection. Atherosclerosis. 2023;19(2):107–114. (In Russ.) DOI: 10.52727/2078-256X-2023-19-2-107-114

[6] Шпагина Л.А., Козик В.А., Шпагин И.С. и др. Особенности фенотипа и эндотипа течения острого коронарного синдрома у медицинских работников, перенесших новую коронавирусную инфекцию // Атеросклероз. 2023. Т. 19, № 2. P. 107–114. DOI: 10.52727/2078-256X-2023-19-2-107-114

[7] Spiryakina YaG, Lomaichikov VV, Petrenko AP, et al. Risk of developing acute coronary syndrome against the background of COVID-19. Attitude to vaccination against coronavirus infection of patients with cardiovascular pathology. International Journal of Heart and Vascular Diseases. 2022;10(33):18–23. (In Russ.) DOI: 10.24412/2311-1623-2022-33.1-18-23

[8] Спирякина Я.Г., Ломайчиков В.В., Петренко А.П. и др. Риск развития острого коронарного синдрома на фоне СOVID-19. Отношение к вакцинации против коронавирусной инфекции пациентов с сердечно-сосудистой патологией // Международный журнал сердца и сосудистых заболеваний. 2022. Т. 10, № 33. С. 18–23. DOI: 10.24412/2311-1623-2022-33.1-18-23

[9] Serebrennikov II, Kopylov FYu, Komarov RN, et al. Organizational and clinical aspects of acute coronary syndrome combined with a new coronavirus infection (SARS-CoV-2). Eurasian Journal of Cardiology. 2023;2:6–11. (In Russ.) DOI: 10.38109/2225-1685-2023-2-6-11

[10] Серебренников И.И., Копылов Ф.Ю., Комаров Р.Н. и др. Организационные и клинические аспекты острого коронарного синдрома, сочетающегося с новой коронавирусной инфекцией (SARS-CoV-2) // Евразийский кардиологический журнал. 2023. № 2. С. 6–11. DOI: 10.38109/2225-1685-2023-2-6-11

[11] Pleshko AA, Kolyadko MG, Russkikh II, et al. Certain features of inflammation and endothelial dysfunction in persons with confirmed new coronavirus infection SARS-CoV-2 and acute coronary artery thrombosis. Cardiology in Belarus. 2022;14:388–395. (In Russ.) DOI: 10.34883/PI.2022.14.4.002

[12] Плешко А.А., Колядко М.Г., Русских И.И. и др. Некоторые аспекты воспаления и эндотелиальной дисфункции у лиц с подтвержденной новой коронавирусной инфекцией SARS-CoV-2 и острым тромбозом коронарных артерий // Кардиология в Беларуси. 2022. Т. 14. С. 388–395. DOI: 10.34883/PI.2022.14.4.002

[13] Shumailova MM. Klinicheskii sluchai infarktopodobnoi ehlektrokardiogrammy u bol’nogo СOVID-19. Translyatsionnaya meditsina. 2022;9(S2):527. (In Russ.)

[14] Шумайлова М.М. Клинический случай инфарктоподобной электрокардиограммы у больного СOVID-19 // Трансляционная медицина. 2022. Т. 9, № S2. С. 527.

[15] Barbarash OL, Kashtalap VV. Non-ST segment elevation myocardial infarction: results of 2021−2022. Fundamental and Clinical Medicine. 2023;8(1):132–142. (In Russ.) DOI: 10.23946/2500-0764-2023-8-1-132-142

[16] Барбараш О.Л., Кашталап В.В. Острый коронарный синдром без подъёма сегмента ST. Итоги 2021–2022 гг. // Фундаментальная и клиническая медицина. 2013. Т. 8, № 1. С. 132–142. DOI: 10.23946/2500-0764-2023-8-1-132-142

[17] Ponomarenko IV, Sukmanova IA, Safonova EA. Clinical and laboratory parameters and frequency of complications in patients with myocardial infarction and COVID-19. Medicine: theory and practice. 2022;(7):18–26. (In Russ.)

[18] Пономаренко И.В., Сукманова И.А., Сафонова Е.А. Клинико-лабораторные показатели и частота осложнений у пациентов с инфарктом миокарда и СOVID-19 // Медицина: теория и практика. 2022. № 7. С. 18–26.

[19] Alekyan BG, Boytsov SA, Ganyukov VI, Manoshkina EM. Impact of the COVID-19 pandemic on myocardial revascularization in patients with acute coronary syndrome in the Russian Federation. Rational Pharmacotherapy in Cardiology. 2022;18(4):411–419. (In Russ.) DOI: 10.20996/1819-6446-2022-08-03

[20] Алекян Б.Г., Бойцов С.А., Ганюков В.И., Маношкина Е.М. Влияние пандемии COVID-19 на реваскуляризацию миокарда у пациентов с острым коронарным синдромом в Российской Федерации // Рациональная фармакотерапия в кардиологии. 2022. Т. 18, № 4. P. 411–419. DOI: 10.20996/1819-6446-2022-08-03

[21] Martynov AI. Methodological recommendations “Features of the course of long-covid infection. Therapeutic and rehabilitation measures.” Therapy. 2022;1 (Supplement):1–147. (In Russ.)

[22] Мартынов А.И. Методические рекомендации «особенности течения long-covid инфекции: терапевтические и реабилитационные мероприятия» // Терапия. 2022. № 1 (Приложение). С. 1–147.

RIGHTS & PERMISSIONS

Eco-Vector